immunoglobulin g + hyaluronidase

**immunoglobulin g + hyaluronidase** is a combination therapy consisting of human immunoglobulin G (IgG) and recombinant human hyaluronidase PH20. IgG replaces antibodies in patients with immune deficiencies, while hyaluronidase degrades hyaluronan in the extracellular matrix, temporarily increasing tissue permeability to allow large-volume, less frequent subcutaneous infusions of immunoglobulin. This method enables enhanced absorption and dispersion of IgG, permitting higher dosing per infusion site, less frequent administration, and home-based treatment with a reduced rate of systemic adverse events compared to intravenous immunoglobulin. Approved indications include replacement therapy in primary immunodeficiency (PID) in adults and children (age thresholds may differ by region) and as maintenance therapy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) after stabilization with IVIG[1][2][3][5][7].

Brand names

HyQvia

Other names

IGHyfSCIG 10%